BioInnovate Conference Showcases Path from Innovation to Scale
More than 200 scientists, founders, and government and industry partners gathered at Weill Cornell Medicine to examine how laboratory discoveries become companies. Reporting across a full day of panels, this piece covered startup pitches for multiple sclerosis therapy and neurodegenerative screening, a fireside chat on where AI genuinely helps clinical drug development, and a discussion of the chemistry bottleneck slowing small-molecule discovery — held together by one argument about what a working innovation ecosystem requires.
View article Work with us on a story like this